Histone deacetylase (
HDAC) inhibitors, such as
trichostatin A and
trapoxin, which were first found in microorganisms, potently and selectively inhibit HDAC
enzymes. They have made a strong contribution to research on HDACs,
chromatin control, abnormal epigenetic control in various diseases and the significance of acetylation in posttranslational modification. Recently,
HDAC inhibitors have been focused on as potential drugs for the treatment of several diseases, including
cancer, although
trichostatin A and
trapoxin show no effects in animal models because of their metabolic instability in vivo. Chemical modification has been conducted in order to overcome this drawback. We discovered the microbial metabolites
FK228 (also known as
FR901228,
romidepsin,
depsipeptide, NSC-630176 and NSC-630176D) and YM753 (
spiruchostatin A). Both compounds have bicyclic structures and represent a novel structural class of
HDAC inhibitor. The
enzyme and
tumor cell growth inhibitory activities of
FK228 were found to be very potent. It also showed potent HDAC inhibitory activity in vivo.
FK228 is the first potent
HDAC inhibitor to undergo clinical development as a potential treatment for solid and hematological
cancers. Due to its dramatic effect in patients with refractory
cutaneous T-cell lymphoma (CTCL), in October 2004 the US Food &
Drug Administration (FDA) granted fast-track status to
FK228 as monotherapy for the treatment of CTCL in patients who have relapsed following, or become refractory to, another systemic
therapy. Thus
HDAC inhibitors such as
FK228 and YM753 have potential as tools for life science studies and also as therapeutic agents for various intractable diseases.